Cancel
Known information
- Has over 25 years of experience in both academic and industrial research and development
- Served as the Director of RNA Science at Moderna, leading the RNA Science Department within Moderna's R&D Platform
- Developed mRNA-based technology for application as a new drug modality in infectious disease, personalized cancer medicine, oncology, autoimmune, and rare disease
- Expanded the mechanistic understanding of mRNA design principles underlying current and future mRNA therapeutics, including Moderna's Spikevax mRNA vaccine for COVID-19
- Spent 20 years at Massachusetts Institute of Technology performing research focused on protein synthesis across all kingdoms of life
- Focused on the role of transfer RNA (tRNA) and RNA modifications in translation, rules of mRNA decoding, genetic code expansion, and ribosome biogenesis
- Co-authored more than 40 publications, book chapters, and patents
- Peer-reviewed publications include PNAS, Nature Communications, Cell Metabolism, and Nucleic Acid Therapeutics
- Co-edited a book on 'Protein Engineering' published by Springer
- Contributed a chapter entitled, 'Specialized Components of the Translational Machinery for Unnatural Amino Acid Mutagenesis: tRNAs, Aminoacyl-tRNA Synthetases, and Ribosomes'
- Earned her M.S. and Ph.D. in microbiology from the University of Innsbruck, Austria
About Alltrna
Alltrna is the world's first tRNA platform company, pioneering tRNA therapeutics to potentially treat thousands of diseases by targeting premature stop codons.
Report inaccurate information
